Abstract
(Am J Obstet Gynecol. 2020;223:433.e1–14) Placenta accreta spectrum (PAS), which includes placenta accreta, placenta increta and placenta percreta, often leads to hysterectomy and large-volume maternal hemorrhage and is a major cause of maternal mortality and morbidity. While maternal outcomes can be improved with planning after an accurate diagnosis, more than 50% of pregnancies complicated by PAS are not diagnosed prior to delivery. A method of reliable, early diagnosis of PAS is needed to improve maternal outcomes. This study used a novel aptamer-based platform for biomarker discovery to explore whether women who experience PAS have a unique protein signature in maternal plasma during the third trimester that may be used to diagnose PAS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
